A randomised, controlled, phase 3 trial by Rolf Issels and colleagues1 on neo-adjuvant chemotherapy alone or with regional hyperthermia for localised, high-risk, soft-tissue sarcoma published in 2010 in The Lancet Oncology is currently the only level 1 evidence in favour of regional hyperthermia for the treatment of soft-tissue sarcoma.2 I believe a bias is present in this analysis because the combined treatment group received more chemotherapy than the chemotherapy alone group (median 8·0 cycles vs 5·0 cycles).
http://ift.tt/2zlAAa6
Τρίτη 31 Οκτωβρίου 2017
[Correspondence] Neo-adjuvant chemotherapy alone or with regional hyperthermia for soft-tissue sarcoma
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου